ZAI LAB LIMITED Earnings Per Share, Basic and Diluted
ZAI LAB LIMITED (ZLAB) reported Earnings Per Share, Basic and Diluted of -$0.09 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-10
- ZAI LAB LIMITED earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.09.
- ZAI LAB LIMITED earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$2.22.
- ZAI LAB LIMITED earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$1.01.
- ZAI LAB LIMITED earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.76.
- ZAI LAB LIMITED earnings per share, basic and diluted for fiscal 2021 was -$7.58.
- ZAI LAB LIMITED earnings per share, basic and diluted for fiscal 2020 was -$3.46.
- ZAI LAB LIMITED earnings per share, basic and diluted for fiscal 2019 was -$3.03.
- ZAI LAB LIMITED earnings per share, basic and diluted for fiscal 2018 was -$2.64.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$0.09 10-Q · filed 2022-05-10 | -$0.56 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$1.02 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$1.79 derived: net income ÷ weighted average shares · filed 2023-05-09 | |
| 2021-12-31 | -$2.22 10-K · filed 2022-03-01 | -$3.24 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$4.99 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$7.58 10-K · filed 2022-03-01 | |
| 2021-09-30 | -$1.01 10-K · filed 2022-03-01 | -$2.76 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$5.34 10-Q · filed 2021-11-09 | -$1.96 derived: net income ÷ weighted average shares · filed 2022-11-09 | |
| 2021-06-30 | -$1.76 10-K · filed 2022-03-01 | -$4.37 10-Q · filed 2021-08-09 | -$1.33 derived: net income ÷ weighted average shares · filed 2022-08-09 | -$1.88 derived: net income ÷ weighted average shares · filed 2022-08-09 | |
| 2021-03-31 | -$0.26 10-Q · filed 2022-05-10 | -$2.64 10-Q · filed 2021-05-10 | -$0.64 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$1.07 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$1.62 derived: net income ÷ weighted average shares · filed 2022-05-10 |
| 2020-12-31 | -$0.88 10-K · filed 2022-03-01 | -$1.72 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.79 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$3.46 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$0.84 10-K · filed 2022-03-01 | -$1.92 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.59 10-Q · filed 2021-11-09 | -$3.28 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2020-06-30 | -$1.08 10-K · filed 2022-03-01 | -$1.74 10-Q · filed 2021-08-09 | -$2.44 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$3.39 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2020-03-31 | -$0.66 10-K · filed 2022-03-01 | -$1.34 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.30 derived: net income ÷ weighted average shares · filed 2022-03-01 | ||
| 2019-12-31 | -$0.68 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.65 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$3.03 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$0.97 derived: net income ÷ weighted average shares · filed 2020-01-21 | -$2.35 6-K · filed 2020-01-21 | |||
| 2019-06-30 | -$1.37 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | -$1.09 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$2.64 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$1.49 6-K · filed 2020-01-21 | ||||
| 2017-12-31 | -$2.32 20-F · filed 2020-04-29 | ||||
| 2016-12-31 | -$3.97 20-F · filed 2019-03-29 | ||||
| 2015-12-31 | -$2.07 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |